drugsTreatmentPhase 2

T3011

T3011 is an experimental small-molecule drug from ImmVira Pharma in phase 2 trials for melanoma, head and neck squamous cell carcinoma and sarcomas, aimed at PD-1 and PD-L1.

T3011 is a small-molecule drug developed by ImmVira Pharma and Shanghai Pharmaceuticals. Its targets are PD-1 and PD-L1. ClinicalTrials.gov describes the intervention as: T3011 will be administered up to 4mL as an intratumoral injection given Q2W. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in melanoma, head and neck squamous cell carcinoma, sarcomas, non-small-cell lung cancer and bladder & urothelial cancer. The largest, NCT06971614, plans to enrol 160 participants with primary completion expected 2028-12-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How targeted therapy works, step by step · animated schematic, not to scale; chosen from the modality "small molecule"

Targeted Therapy →

Modality

small molecule

Mechanism

Small-molecule drug directed at PD-1 and PD-L1, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

T3011

intervention: T3011

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.